Table 1.
Clinical features of RRSM patients
| Baseline (0 infusion) t0 | <12 months | >12 months | ||
|---|---|---|---|---|
| 4–12 infusions (t1–t3) | 13–24 infusions (t4) | >24 infusions (t5) | ||
| F/M (n) | 8/14 | 13/17 | 17/5 | 9/2 |
| Total | 22 | 30 | 22 | 11 |
| STRATIFY JCV®a +/− t0 | 4/18 | 5/25 | ||
| STRATIFY JCV®a +/− t3 | – | 13/17 | 6/16 | 3/8 |
| Mean age (±stand. dev.) | 30.6 (±6.8) | 35 (±8.4) | 38.2 (±7.6) | 39.7 (±10.6) |
| Mean of months of disease (±stand. dev.) | 84 (±85.7) | 107 (±89.7) | 100 (±79.2) | 75.6 (±44.9) |
| Mean EDSSb (±stand. dev.) | 1.9 (±1.3) | 2.1 (±1.0) | 2.2 (±1.1) 2 (1–4) |
2.2 (±1.0) 2 (1–4) |
| No therapyc (n) | 9 | 9 | 5 | 1 |
| Interferonc (n) | 13 | 18 | 12 | 8 |
| Glatimer acetatec (n) | – | 3 | 5 | 2 |
F female, M male, n number of patients, stand. dev. standard deviation
aSTRATIFY JCV®: two-step virus-like particle-based enzyme-linked immunosorbent assay (ELISA) was performed at t0 and t3 (1 year of treatment), to detect specific anti-JC virus antibodies in serum of the enrolled subjects (Gorelik et al. 2010)
bEDSS: Kurtzke Expanded Disability Status Scale, with values ranging from 0 (normal neurological examination) to 10 (bedridden patient) (Kurtzke 1983)
cTherapy before starting with natalizumab treatment